Loading component...
What is the Oncotype DX® test, and what makes it unique?
The Oncotype DX Breast Recurrence Score® test has been developed for patients with early-stage HR+, HER2- breast cancer to:
- Identify those patients who may benefit from chemotherapy1,2
- Determine the magnitude of chemotherapy benefit1-5
- Support treatment decisions1-5
Chemotherapy can cause both short- and long-term side effects affecting current and future health, quality of life, family life and work life.6-8 The vast majority of patients with HR+, HER2- early-stage breast cancer do not benefit from adjuvant chemotherapy.9
Loading component...
Prediction of chemotherapy benefit based on prospective clinical trials makes the Oncotype DX test unique.
Loading component...
Loading component...
Loading component...
Loading component...
Loading component...
Loading component...
Loading component...
Abbreviations
CT, chemotherapy
ET, endocrine therapy
HER2–, human epidermal growth factor receptor 2 negative
HR+, hormone receptor positive
N+, node-positive
N0, node-negative

